TF and breast neoplasm: With these two high-throughput genome-wide data sets from primary breast tumors (BRCA-EU and ER ChIP-seq), we aimed to decipher the in vivo mutational landscape underlying this lineage specifying TF-ER and identify the regulatory impact of non-coding somatic mutations associated with breast cancer.